相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression
Hak-Su Kim et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Erythropoietin receptor contributes to melanoma cell survival in vivo
S. M. Kumar et al.
ONCOGENE (2012)
Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke
Manuela Mengozzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
Matti Aapro et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Blocking Epidermal Growth Factor Receptor Activation by 3,3′-Diindolylmethane Suppresses Ovarian Tumor Growth In Vitro and In Vivo
Prabodh K. Kandala et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
A review of PARP inhibitors: from bench to bedside
C. Underhill et al.
ANNALS OF ONCOLOGY (2011)
PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1
Shuai Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy
Michiaki Kohno et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
PARP inhibitors - current status and the walk towards early breast cancer
Jennifer Glendenning et al.
BREAST (2011)
Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors
Johann Sebastian de Bono et al.
CANCER CELL (2011)
Erythropoietin enhances immunostimulatory properties of immature dendritic cells
F. Rocchetta et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
The role of targeted therapy in ovarian cancer
Susana Banerjee et al.
EUROPEAN JOURNAL OF CANCER (2011)
Targeting the erythropoietin receptor on glioma cells reduces tumour growth
Elodie A. Peres et al.
EXPERIMENTAL CELL RESEARCH (2011)
Therapeutic potential of PARP inhibitors for metastatic breast cancer
Sheeba Irshad et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation
Wu Zhang et al.
ONCOLOGY REPORTS (2011)
Erythropoietin: A Hormone with Multiple Functions
Matilde Lombardero et al.
PATHOBIOLOGY (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Resistance to MEK Inhibitors: Should We Co-Target Upstream?
Poulikos I. Poulikakos et al.
SCIENCE SIGNALING (2011)
Histone ADP-ribosylation in DNA repair, replication and transcription
Simon Messner et al.
TRENDS IN CELL BIOLOGY (2011)
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
M. Javle et al.
Therapeutic Advances in Medical Oncology (2011)
Hypoxia and adrenergic function: Molecular mechanisms related to Egr-1 and Sp1 activation
T. C. Tai et al.
BRAIN RESEARCH (2010)
Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models
Kazushi Watanabe et al.
CLINICAL CANCER RESEARCH (2010)
Future Directions in Castrate-Resistant Prostate Cancer Therapy
Emmanuel S. Antonarakis et al.
CLINICAL GENITOURINARY CANCER (2010)
Erythropoietin Receptor Signaling Mitigates Renal Dysfunction-Associated Heart Failure by Mechanisms Unrelated to Relief of Anemia
Atsushi Ogino et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
Zhanzhong Shi et al.
MOLECULAR CANCER RESEARCH (2010)
Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway
Ping Fu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Ann F. Chambers
CANCER RESEARCH (2009)
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
Terry J. Gaymes et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
The role of poly(ADP-ribosyl)ation in epigenetic events
Delphine Quenet et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells
Lilach Lifshitz et al.
MOLECULAR IMMUNOLOGY (2009)
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors
Dana Inbar-Rozensal et al.
BREAST CANCER RESEARCH (2009)
Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals
Chhanda Bose et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)
Erythropoietin receptor-mediated Egr-1 activation:: Structural requirements and functional implications
Christoph Schulze et al.
CELLULAR SIGNALLING (2008)
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
W. Lee Kraus
CURRENT OPINION IN CELL BIOLOGY (2008)
Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells
M. Carbone et al.
ONCOGENE (2008)
Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism
Sumaya N. Hamadmad et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
PARP-1 activation in the ERK signaling pathway
Malka Cohen-Armon
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
Lucio Tentori et al.
EUROPEAN JOURNAL OF CANCER (2007)
Clinical experience of MEK inhibitors in cancer therapy
Ding Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
DNA-independent PARP-1 activation by phosphorylated ERK2 increases EIk1 activity: A link to histone acetylation
Malka Cohen-Armon et al.
MOLECULAR CELL (2007)
Proximal cyclic AMP response element is essential for exendin-4 induction of rat EGR-1 gene
Jung-Hoon Kang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier
Stephen G. Grant et al.
PATHOLOGY & ONCOLOGY RESEARCH (2007)
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
Mohanraj Rajesh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Local administration of the poly ADP-ribose polymerase (PARP) inhibitor, PJ34 during hindlimb ischemia modulates skeletal muscle reperfusion injury
Mark F. Conrad et al.
JOURNAL OF SURGICAL RESEARCH (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise
M. - Brines et al.
KIDNEY INTERNATIONAL (2006)
Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia
RD Lester et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Turning cells red: signal transduction mediated by erythropoietin
TD Richmond et al.
TRENDS IN CELL BIOLOGY (2005)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies
M Mittelman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
EPO receptor-mediated ERK kinase and NF-κB activation in erythropoietin-promoted differentiation of astrocytes
SM Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells
BB Beleslin-Cokic et al.
BLOOD (2004)
PARP-1, a determinant of cell survival in response to DNA damage
WJ Bouchard et al.
EXPERIMENTAL HEMATOLOGY (2003)
Histone acetylation: a switch between repressive and permissive chromatin - Second in review series on chromatin dynamics
A Eberharter et al.
EMBO REPORTS (2002)
Histone deacetylase as a therapeutic target
OH Krämer et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2001)
Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases
S Gobeil et al.
CELL DEATH AND DIFFERENTIATION (2001)
Detection of c-fos expression in benign and malignant musculoskeletal lesions
JS Weisstein et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2001)
Histone acetylation and chromatin remodeling
PD Gregory et al.
EXPERIMENTAL CELL RESEARCH (2001)
Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice
Y Yasuda et al.
BRITISH JOURNAL OF CANCER (2001)
Signaling induced by erythropoietin and stem cell factor in UT-7/Epo cells: Transient versus sustained proliferation
CL Erickson-Miller et al.
STEM CELLS (2000)
分享论文
